These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2963295)

  • 1. [Idiopathic intracranial hypertension during treatment of Cushing's disease with mitotane].
    Marechaud R; Boissonnot M; Holderer-Fieuzal S; Gouet D; Boissonnot L
    Presse Med; 1987 Dec; 16(42):2131. PubMed ID: 2963295
    [No Abstract]   [Full Text] [Related]  

  • 2. 18 years mitotane therapy for intractable Cushing's disease.
    Kawai S; Ichikawa Y; Kaburaki J; Yoshida T
    Lancet; 1999 Sep; 354(9182):951. PubMed ID: 10489980
    [No Abstract]   [Full Text] [Related]  

  • 3. Cushing's disease.
    Trainer PJ; Besser M
    Lancet; 2000 Jan; 355(9197):68. PubMed ID: 10615912
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitotane-induced febrile pancytopenia: a first case report in paraneoplastic Cushing's syndrome.
    Andrès E; Vinzio S; Goichot B; Schlienger JL
    Eur J Endocrinol; 2001 Jan; 144(1):81. PubMed ID: 11174841
    [No Abstract]   [Full Text] [Related]  

  • 5. Mitotane. Spironolactone antagonism in Cushing's syndrome.
    Wortsman J; Soler NG
    JAMA; 1977 Dec; 238(23):2527. PubMed ID: 578890
    [No Abstract]   [Full Text] [Related]  

  • 6. [Benign intracranial hypertension following the suspension of corticotherapy in a female patient previously operated on for Cushing's disease].
    Lucas A; Coll J; Salinas I; Sanmartí A
    Med Clin (Barc); 1991 Oct; 97(12):473. PubMed ID: 1753818
    [No Abstract]   [Full Text] [Related]  

  • 7. [Neurotoxicity of mitotane therapy of adrenocortical carcinoma (5 cases) and Cushing's syndrome (7 cases)].
    du Rostu H; Krempf M; Mussini JM; Murat A; Guillon J; Charbonnel B
    Presse Med; 1987 May; 16(19):951-4. PubMed ID: 2954144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [12 years of medical treatment of Cushing's disease. Long-term use of Op, DDD in 46 cases].
    Bricaire H; Luton JP
    Nouv Presse Med; 1976 Feb; 5(6):325-9. PubMed ID: 1264700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiences with Lysodren treatment of Cushing's syndrome in dogs].
    Opitz M; Lettow E; Loppnow H; Grevel V
    Tierarztl Prax; 1983; 11(4):507-20. PubMed ID: 6658774
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of mitotane on Alternaria alternata infection in Cushing's syndrome.
    Kasperlik-Zaluska AA; Bieluńska S
    Lancet; 1991 Jan; 337(8732):53-4. PubMed ID: 1670675
    [No Abstract]   [Full Text] [Related]  

  • 13. The medical treatment of Cushing's syndrome.
    Miller JW; Crapo L
    Endocr Rev; 1993 Aug; 14(4):443-58. PubMed ID: 7693447
    [No Abstract]   [Full Text] [Related]  

  • 14. [Letter: Idiopathic hemochromatosis and Cushing's disease].
    Schrub JC; Courtois H
    Nouv Presse Med; 1975 Mar; 4(13):972-3. PubMed ID: 1144042
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Cushing's disease with o, p'-DDD (author's transl)].
    Nakagawa K; Ito S; Ohara T; Kubo M; Horikawa H
    Horumon To Rinsho; 1981 Sep; 29(9):1135-9. PubMed ID: 7326856
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of Cushing's disease with op' DDD].
    Golik A; Rosenberg T; Gilboa Y
    Harefuah; 1975 Dec; 89(12):563-4. PubMed ID: 1218835
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Cushing's syndrome with chloditane].
    Komissarenko IV
    Klin Med (Mosk); 1976 Sep; 54(9):122-7. PubMed ID: 1003908
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of cholesterol oxidase in a patient with Cushing's syndrome.
    Davey DD; Alber DB; Ryder KW; Jones JM; Hostetler ML; Moorehead WR; Oei TO
    Clin Chem; 1984 Apr; 30(4):572-4. PubMed ID: 6584245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease.
    Bruno OD; Hoschoian JC; Andrada JA
    Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150
    [No Abstract]   [Full Text] [Related]  

  • 20. [Change in blood coagulation in Itsenko-Cushing's disease under the influence of chloditan treatment].
    Vasiukova EA; Pisarskaia IV
    Klin Med (Mosk); 1976 Aug; 54(8):108-10. PubMed ID: 1011762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.